Trial · NCT05732454
Results by group192
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 192
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16 | DB Period: Etrasimod 2 mg | 3.3 | 3.28 to ? | Percentage of Participants | |
| Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16 | DB Period: Placebo | 7.1 | 4.87 to ? | Percentage of Participants | |
| Part 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 16 | DB Period: Etrasimod 2 mg | 23.3 | 7.72 to ? | Percentage of Participants | |
| Part 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 16 | DB Period: Placebo | 14.3 | 6.61 to ? | Percentage of Participants | |
| Part 1, DB Period: Percent Change From Baseline in EASI Score at Week 16 | DB Period: Etrasimod 2 mg | -53.87 | Standard Error 9.007 | Percent change | |
| Part 1, DB Period: Percent Change From Baseline in EASI Score at Week 16 | DB Period: Placebo | -24.65 | Standard Error 9.533 | Percent change | |
| Part 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality) | DB Period: Etrasimod 2 mg | 16 | Participants | ||
| Part 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality) | DB Period: Placebo | 8 | Participants | ||
| Part 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation | DB Period: Etrasimod 2 mg | 1 | Participants | ||
| Part 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation | DB Period: Placebo | 0 | Participants | ||
| Part 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality) | DB Period: Etrasimod 2 mg | 0 | Participants | ||
| Part 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality) | DB Period: Placebo | 0 | Participants | ||
| Part 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality) | DB Period: Etrasimod 2 mg | 2 | Participants | ||
| Part 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality) | DB Period: Placebo | 1 | Participants | ||
| Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities | DB Period: Etrasimod 2 mg | 22 | Participants | ||
| Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities | DB Period: Placebo | 13 | Participants | ||
| Part 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks | DB Period: Etrasimod 2 mg | Pre-dose/Day 1: AV conduction: First-degree AV Block | 1 | Participants | |
| Part 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks | DB Period: Placebo | Pre-dose/Day 1: AV conduction: First-degree AV Block | 0 | Participants | |
| Part 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks | DB Period: Etrasimod 2 mg | 4 hrs post-dose/Day 1: QTCF (msec), single beat:>= 450 (male) or >= 470 (female) | 1 | Participants | |
| Part 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks | DB Period: Placebo | 4 hrs post-dose/Day 1: QTCF (msec), single beat:>= 450 (male) or >= 470 (female) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05732454/results